Study of Personalized Cancer Treatment Based on Molecular Profiles for Patients With Aggressive Cancers and Poor Prognoses

What this Trial Is About

Researchers are investigating the use of molecular profile-based evidence to guide personalized cancer treatment for patients with aggressive cancers that have poor prognoses. This study is open-label and non-randomized, including patients with various cancer types to see if matching treatment to molecular changes can be effective across different cancers. The aim is to evaluate the feasibility of this molecular matching strategy for individualized therapy. Patients will be divided into three groups based on disease status and treatment history Group 1 includes patients with localized disease who have not received prior treatment and are eligible for neoadjuvant therapy, have unresectable disease, or are medically unfit for surgery Group 2 includes treatment-nave patients with metastatic disease and Group 3 includes patients with metastatic or unresectable disease who have received at least one prior systemic therapy. Molecular profiling of tumor tissue or blood will guide treatment recommendations by a Molecular Tumor Board. Patients receiving matched therapy form Arm A, while those receiving unmatched therapy or with no molecular alterations form Arm B. Participants will undergo molecular profiling if not already done, and their treatment will be guided accordingly. Researchers will assess feasibility by measuring enrollment success, turnaround times, and actionable molecular findings. The primary outcome is the proportion of patients receiving matched treatment at eight months. Secondary outcomes include the identification of actionable alterations and treatments recommended by the Molecular Tumor Board. Participants will be monitored throughout treatment, with assessments to evaluate treatment response and safety.

Investigation of Profile-related Evidence Determining Individualized Cancer Therapy for Patients With Aggressive Malignancies and Poor Prognoses